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Abstract  
          Background - recently, insulin-dependent diabetes mellitus, can be treated by pancreatic islet  allotransplantation.   
           Methods - This retrospective study involves 137 patients from the Surgery Department of Colentina Clinical Hospital, 
Bucharest, in the July 2000 - July 2008 period, who underwent pancreatic resections, the number of patients who developed 
pancreatogenic diabetes and their selection for the pancreatic islet transplantation. 
           Results - After pancreatectomy, 70 patients are diagnosed with diabetes, and 42 with prediabetic stages (IFG and IGT). 61 of 
these had average glycemic excursions (MAGE) over the normal, and 31 of the 70 patients diagnosed with diabetes, presented 
hypoglycemic episodes during treatment.  
           Conclusion - The present criteria of patient selection for pancreatic islets transplantation are limited and can be applied to a 
small number of patients. 
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Introduction 
Insulin-dependent diabetes can be treated by 
complex dietary measures and insulin administration, and 
more recently by pancreatic/pancreatic islets 
allotransplantation.[1] 
 The whole pancreas transplantation encompasses 
two categories of major risks and complications: 
1) the immunosuppressive treatment;  
2) the risk of major surgery in patients with a 
chronic condition. 
    Pancreatic islets transplantation seems more 
reasonable than the whole pancreas transplantation. It 
demands a shorter surgical procedure, involving less 
invasive methods of anesthesia for the body, but requires 
a very complicated technology of preparing the pancreatic 
islets. [2] 
  Therefore, the risks and complications of 
immunosuppressant treatment currently remain research 
heads in developing microcapsules for pancreatic islet 
transplantation that do not require an immunosuppressant 
treatment. The permeability properties of these 
microcapsules allow the penetration of nutrients and 
glucose and elimination of insulin secreted by pancreatic 
islet.[3] 
 Moreover, current studies suggest that the actual 
number of beneficiaries of a possible pancreatic islet 
transplant is very low. For this reason, research is headed 
to stem cells use for diabetes therapy because of their 
multipotency and recent applications in the treatment of 
serious diseases (Alzheimer's disease, cardiac pathology, 
etc.).[4] 
Objectives 
This paper is elaborated on the pancreatogenic 
diabetes patient selection criteria for the pancreatic islet 
transplantation. 
Materials and methods 
This study involves 137 patients from the Surgery 
Department of “Colentina” Clinical Hospital, Bucharest, 
from July 2000 to July 2008. 
Inclusion criteria: age above 18 years old, known 
pancreatic pathology (acute/chronic pancreatitis, 
pancreatic cancer) 
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Exclusion criteria: patients known to suffer from 
acute/chronic pancreatitis and pancreatic cancer, who did 
not undergo pancreatic resection. 
The main indication for surgery was the lack of 
response to pain medication, eating disorders, weight 
loss, repeated periods of hospitalization, decreased work 
capacity and imagistic evidence of morphological changes 
of the pancreas. 
Only subtotal pancreatectomies were conducted in 
this study. 
The variables in this study are represented by the 
indications/contraindications in the pancreatic islet 
transplantation stated by the Edmonton protocol. 
 
Indications for pancreatic islet transplantation (According 
to the Edmonton protocol) [5] 
 
• Patients with type I diabetes aged between 18 and 65 
years old who have been diagnosed with diabetes for 5 
years; 
• Severe hypoglycemic answers; 
• Unstable diabetes:  
1. Metabolic instability sufficient to cause the 
worsening of the patient's lifestyle and 
endangering his life, even if the patient uses a 
strict insulin administration schedule and blood 
glucose monitoring is done 4 times a day  
2. Metabolic instability manifested by chaotic 
blood glucose profile  
3. Number of hypoglycemic episodes or 
ketoacidosis (two episodes that required 
assistance with hospitalization for hypo or 
hyperglycemia in the last 12 months)  
4. Increase in mean amplitude glycemic 
excursions (MAGE) (> 6.6 mmol / l (118.8 mg / 
dl) while normally it is <3.5 mmol/l (63mg/dl))  
5. Altered way of life, determined by the number 
of hospital admissions per year (two or more), 
the absence from work or school (4 weeks or 
longer), or the inability to cope with everything, 
alone at home or in another environment  
• Reversible secondary diabetic complications:  
1. progressive microalbuminuria receive 
treatment (proteinuria <3g/day)  
even on ACE inhibitors  
2. difficulties given by documented 
autonomic/peripheral neuropathy 
3. documented proliferative retinopathy  
• negative C peptide (<0.2 ng/ml after iv administration of 
5 grams of arginine)  
• Doses of insulin per day <0.7 U / per kg of bodyweight / 
day)  
 
Contraindication for pancreatic islet transplantation” [5] 
• severe coexisting cardiac disease:  
1. myocardial infarction - in the last 6 months 
2. angiographically record of irreversible CAD 
(coronary artery disease) 
3. cardiac ejection fraction <40%  
• Alcohol or other substance abuse, including smoking (to 
be stopped 6 months before transplant)  
• Major psychiatric disorders  
• Active infections: hepatitis C, hepatitis B, HIV positive,  
Mantoux test (skin reaction to PPD)  
• History of malignancy (unless they have a free interval of 
at least 5 years)  
• Portal hypertension  
• Body weight index over 26, or weight> 70 kg in women 
and> 75 kg in men  
• C peptide> 0.2 ng / ml  
• Age below 18 or more than 65 years old  
• Creatinine clearence <60 ml/min/1, 73 meters  
• History of non-compliance to medication, including 
immunosuppressive  
• HbA1c> 10%  
• Untreated proliferative retinopathy  
• Positive pregnancy test   
• Uncontrolled hyperlipidemia  
• Diseases that require chronic administration of steroids  
• Symptomatic biliary lithiasis  
• Coagulopathy or conditions requiring long-term 
administration of anticoagulant therapy 
 
Patients with insulin-dependent diabetes who 
address to transplant teams are registered on waiting lists 
in the following situations: 
1. If they have both diabetes and concomitant 
chronic renal failure and are candidates for a kidney 
transplant, and can thus solve both conditions at the same 
time, or in turns (double transplant / post renal 
transplant).[6] 
2. On grounds of benign pancreatic disease 
severity, they undergo a total or subtotal pancreatectomy. 
Most frequently, this happens in severe chronic 
pancreatitis, but also in some pancreatic trauma. 
3. In patients with type I diabetes (hypoglycemia, 
coma, etc.) difficult to control  
Results 
Patients’ distribution by admission time and 
pathology 
Of the patients who required pancreatectomy during 
July 2000 - July 2008, 23.35% of them were diagnosed 
with acute pancreatitis, 47.45% with chronic pancreatitis 
and 29.2% with pancreatic cancer. 
Although patients who have undergone a 
pancreatectomy for pancreatic cancer, would fit in terms of 
postoperative diabetes in the selection criteria for 
pancreatic islet transplantation of pancreatic islands, the 
very disease they had surgery for, excludes them. 
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 Table 1. Distribution by hospital admission year and diagnosis 
Admission year  Diagnosed with acute 
pancreatitis 
Diagnosed with 
chronic pancreatitis 
Diagnosed with 
pancreatic cancer 
Diagnosed with 
pancreatic cancer 
2001  5  6  4  15 
2002  4  9  6  19 
2003  3  9  4  16 
2004  4  8  7  19 
2005  4  7  6  17 
2006  5  10  3  18 
2007  3  7  6  16 
2008  4  9  4  17 
Total  32  65  40  137 
 
Age at hospital admission 
 The chart below shows that most of the patients in  
 
the study group are aged between 45 and 65 years old. 
Roughly, there are 2 times more males than females. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Age distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood glucose levels 
Fasting blood glucose levels 
were monitored in all patients during 
hospitalization. As it is clear from the 
evidence presented, the number of 
patients with blood glucose values 
over 120 rose significantly from 44 
patients preoperatively, to 70 
patients postoperatively, constituting 
51.09% of all patients. The 42 
patients with postoperative blood 
glucose levels between 101 and 120 
mg / dl (IFG-impaired fasting 
glucose) had glucose tolerance test 
after surgery. Two hours after 
glucose ingestion 34 of them had 
blood glucose values greater than 
140mg/dl. They were diagnosed with 
IGT (impaired glucose tolerance), 
prediabetic stage that should be kept 
under observation. 
 
 
Fig.2.  Blood glucose level 
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Patients with diabetes and prediabetic stages 
(IFG,IGT) had their mean glycemic excursions (MAGE) 
tracked. 61 of the 112 patients (50% of total) had mean 
values that exceeded 3mg/dl (value considered standard). 
 
Hospital stay 
The average length of hospitalization of patients  
 
with no complications was of 10 days (range: 8-14 days) 
and for those that had complications, the average length 
of stay was of 41 days (range: 32-50 days). None of the 
patients who underwent further surgery required distal 
pancreatic stump resection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Number of hospital admissions 
 
Patients altered their lifestyle postoperatively due to 
long periods of hospital stay, along with sick leave, eating 
restraints and postoperative drugs. The number of yearly 
admissions to hospital (two or more), or absence from 
work /school (for 4 weeks or longer), or the inability to 
cope with everything alone at home or in another 
environment contributed to lifestyle alteration too. 58 
patients (74.28% of the total 70 diagnosed with diabetes) 
had transplant indication due to their postoperative altered 
lifestyle. 
 
Unstable diabetes 
18 out of the 70 patients postoperatively diagnosed 
with diabetes, had characteristics of unstable diabetes 
like: life threatening metabolic instability, even if patient 
was under insulin treatment and blood glucose monitoring 
was done 4 times per day. Metabolic instability manifested 
by chaotic blood glucose levels and episodes of 
hypoglycemia or ketoacidosis (two episodes that required 
assistance with hospitalization for hypo/ hyperglycemia in 
the last 12 months). A total of 32 patients experienced 
severe hypoglycemic responses, constituting 45.71% of 
the total of 70 patients with diabetes.  
Neurological and ophthalmologic examinations for 
early detection of potentially reversible secondary 
complications of diabetes were performed postoperatively 
during hospitalization in “Colentina” Clinical hospital. 
 
Autonomous or peripheral neuropathy (indication 
for pancreatic islet transplantation) was diagnosed in 16 
patients (22.85% of the postoperative diabetic patients), 
with equal sex distribution. It is the most common form of 
diabetic neuropathy. 
 
Autonomic neuropathy (autonomic) results from 
damage to the autonomic nervous system. These nerves 
are involved in involuntary body functions such as 
heartbeat, blood pressure, perspiration, digestion, kidney 
function and some aspects of sexual function. This is a 
common form of diabetic neuropathy. 
 
Focal neuropathy affects a single nerve, most 
commonly in the wrist, thigh or leg. It may also affect 
nerves in the back and anterior thorax and those that 
control eye muscles. Carpal tunnel syndrome often occurs 
in people who have diabetes but not focal neuropathy. 
Focal neuropathy usually appears suddenly and it is the 
least frequent form of diabetic neuropathy.[7]  
There is no recommended protocol for screening 
autonomous or focal neuropathy, but during regular 
medical examination multiple signs and symptoms should 
be alarming: pain of any intensity and localization, 
weakness or motor disorder, changes in digestion, kidney 
function or sexual behavior, sweating or dizziness.[7] 
There is no cure for diabetic neuropathy. Once 
installed, the treatment focuses on secondary prevention 
(removal of precipitating factors) consisting of keeping 
blood glucose levels in a certain target. A tight control of 
blood glucose is to maintain an average glycosylated 
hemoglobin [HbA1c] under 7%, for a period of 2 to 3 
months.  
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Microalbuminuria is an important independent risk 
marker for proliferative diabetic retinopathy, as well as for 
hypertension. Microalbuminuria over 100mg/24h is 
associated with progressive decrease of glomerular 
filtration rate (by 3-4 ml/min/year), and is strongly 
predictive for the occurrence of proteinuria and chronic 
renal failure[8]. 10 out of 14 patients discovered with 
microalbuminuria during the study, developed proteinuria 
(300-3000g/day), necessary for the patient to have 
treatment indication, but 8 of the 14 patients had creatinin 
a clearance level of <60 ml/min/1,73m, this being among 
the contraindications. Pancreatic islet transplantation is 
specifically indicated in patients with type I diabetes who 
have a functional renal graft and are already 
immunosuppressed. 
 
Diabetic retinopathy was diagnosed by the 
ophthalmologist in seven patients (10%), 5 of them having 
no previous treatment for the condition. Proliferative 
retinopathy is an indication of pancreatic islet 
transplantation, but untreated becomes a 
contraindication.[8] 
Islet secretory function was also assessed by the 
determination of C peptide and glycosylated hemoglobin 
HbA1c.  
 
C peptide is a 31 amino acids chain that links the A 
and B chains of insulin in the proinsulin molecule. 42 
patients had postoperative levels of C peptide above 0.2 
ng/ml. C peptide above 0.2ng/ml is among the 
contraindications of the procedure. 
 
Glycosylated hemoglobin - the normal maximum 
is 2.2-5%, but the goal in diabetes is to keep it under 7%. 
HbA1C determination has become mandatory in 
assessing therapeutic efficiency and the degree of 
metabolic balance. HbA1C has given important 
information in blood glucose levels in the past three 
months. Unlike a determination of glucose, which shows 
blood glucose level at a certain time and thus may mislead 
us, HbA1C shows a history of blood glucose levels, 
therefore it is known as "glucose memory".  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the 70 patients with postoperative diabetes, 15 
(21.42%) had postoperative HbA1c values> 10%, this 
value representing a contraindication. 
Active ethanol abuse, as well as other substance 
abuse and smoking (which should be stopped 6 months 
before transplantation), were correlated with a history of 
non-compliance to medication. Patient compliance is very 
important due to the postoperative permanent 
immunosuppressive treatment. These factors are among 
the contraindications of the process and were 
encountered in 39 patients (55.71% of the total of 70 
patients). 
Diseases requiring long-term administration of 
anticoagulant therapy are also a contraindication. In this 
study, we encountered deep recurrent thromboembolism 
in seven patients (10%), atrial fibrillation in 8 patients 
(11.42%) and one case of ocular central vein thrombosis, 
(1.42%).  
Three patients (4.28%) required chronic 
administration of steroids, one with asthma and two with 
rheumatoid arthritis. 
There were no cases of HIV infection or positive 
Mantoux test (skin reaction to PPD). Hepatitis B (31 
patients-44.28%) and hepatitis C (9 patients-12, 85%) 
were the active infections encountered in these patients. 
  Major psychiatric disorders, part of the 
contraindications of the procedure (organic personality 
disorder, schizophrenia, paranoid disorder) were detected 
in five of the 70 patients (7.14%).  
20% of the patients (14 patients) had treatment-
resistant hyperlipidemia and 43 patients (61.42%) a body 
mass index of (BMI)> 26.  
Severe cardiac conditions are a contraindication: 
myocardial infarction in the last 6 months -3 patients 
(4.28%), angiographically evidenced coronary artery 
disease-22 patients (31.42%), cardiac ejection fraction 
<40% -9 patients (12.85%).  
Portal hypertension was diagnosed in 27 patients 
(38.57% of the studied group).   
No other malignancies were present and 28 patients 
(40%) had a concomitant colecistectomy.   
 
 Conclusion 
HbA1c
>10%
21%
7-10%
46%
<7%
33%
>10%
7-10%
<7% Given these results, we conclude that the selection 
criteria of patients are limitative. Pancreatic islet 
transplantation indications and contraindications should be 
reviewed or medical research interest should move toward 
stem cells use, in order to establish a better treatment for 
pancreatogenic diabetes.  
Fig.4. HbA 1C 
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